rs167769 — STAT6

Intronic variant in STAT6 (intron 2) that forms a functional haplotype with rs324011; the T allele increases STAT6 promoter activity and is associated with elevated serum IgE, atopic dermatitis, eczema herpeticum susceptibility, and eosinophilic esophagitis relapse through enhanced Th2 signaling

See your personal result for STAT6

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

STAT6 rs167769 — The Second Intron Switch That Amplifies Your Allergy Thermostat

STAT6 (Signal Transducer and Activator of Transcription 6)11 STAT6 (Signal Transducer and Activator of Transcription 6)
A transcription factor activated by IL-4 and IL-13 signaling; when these cytokines bind their receptor, STAT6 becomes phosphorylated, dimerizes, and translocates to the nucleus to switch on genes for IgE production, eosinophil recruitment, and airway remodeling — the cellular signature of allergic disease sits at the center of the Th2 immune axis. The rs167769 variant is located in intron 2 of the STAT6 gene on chromosome 12q13, approximately 1,600 base pairs downstream of its haplotype partner rs324011. Together, these two intronic variants form a functional regulatory unit that controls how much STAT6 protein the cell produces in response to inflammatory signals.

The Mechanism

Deep sequencing of the STAT6 intron 2 regulatory region, published by Schedel et al. 200922 Schedel et al. 2009
J Allergy Clin Immunol; identified rs167769 among intronic variants modulating STAT6 expression; T alleles of both rs324011 and rs167769 significantly increased STAT6 promoter activity in luciferase reporter assays, revealed that the T allele at rs167769, like the T allele at rs324011, significantly increases STAT6 promoter activity compared to the C allele. When both T alleles are present on the same chromosome — the rs167769-T / rs324011-T haplotype — the upregulation of STAT6 transcription is most pronounced. The precise mechanism for rs167769 is less fully characterized than for rs324011 (which creates a new NF-κB binding site), but the functional assay evidence for both SNPs acting in concert on STAT6 promoter activity is consistent and replicated.

The consequence of elevated STAT6 expression is amplified Th2 signaling downstream: more IgE class switching in B cells, enhanced eosinophil recruitment, and greater IL-4 and IL-13 production in a feed-forward loop. This molecular amplification is measurable as elevated total serum IgE — the circulating antibody class responsible for immediate hypersensitivity reactions — and manifests clinically as increased susceptibility to atopic dermatitis, asthma, allergic rhinitis, and, through a separate mechanism, eosinophilic esophagitis.

The Evidence

The functional and clinical significance of the rs167769/rs324011 haplotype was established in a Taiwanese pediatric cohort by Lee et al. 201533 Lee et al. 2015
Taiwan Children Health Study; genotyped STAT6 variants in childhood atopic dermatitis; J Dermatol Sci 2015, which showed the combined two-SNP haplotype was significantly associated with childhood atopic dermatitis at global p=0.0018 — a stronger signal than either variant alone. rs167769 individually showed borderline significance (OR 1.21, 95% CI 0.99–1.49), consistent with its role as a haplotype component rather than an independent major-effect variant.

An important additional phenotype emerged from work on eczema herpeticum (EH) — a dangerous disseminated herpes simplex virus infection that occurs predominantly in atopic dermatitis patients with barrier defects and skewed Th2 immunity. Howell et al. 201144 Howell et al. 2011
J Allergy Clin Immunol; 444 white AD patients genotyped for 10 STAT6 SNPs; studied susceptibility to disseminated viral skin infections found that rs167769 C allele was significantly protective against eczema herpeticum (OR 0.65, 95% CI 0.43–0.98, p=0.027), meaning T allele carriers have elevated risk for this viral complication on top of atopic dermatitis. The strongest STAT6 signal in that study involved a 2-SNP haplotype including rs167769 (24.9% frequency in EH cases vs 9.2% in controls, P=5.17×10⁻⁶), indicating the variant plays a mechanistic role in the impaired antiviral immunity associated with STAT6 overexpression.

In pediatric gastroenterology, Mougey et al. 202155 Mougey et al. 2021
Clin Gastroenterol Hepatol; 73 children with EoE on PPI maintenance therapy found that rs167769 (in high linkage disequilibrium with rs324011 and rs12368672, r²≥0.8) conferred a 2.3- to 2.8-fold increased odds of eosinophilic esophagitis relapse after one year of reduced-dose proton pump inhibitor maintenance. This suggests the STAT6 haplotype is a pharmacogenomic marker for EoE treatment durability.

Practical Implications

For T allele carriers, the elevated STAT6 expression lowers the threshold for Th2 immune activation. Total serum IgE — the most accessible clinical readout of Th2 axis activity — can quantify how active this pathway is and how it responds to interventions. For individuals with confirmed atopic dermatitis, the rs167769-T genotype adds genetic context to the elevated STAT6 tone identified by rs324011-T, reinforcing the biological case for IL-4/IL-13 pathway-directed therapy with dupilumab when disease is moderate to severe.

In eosinophilic esophagitis, T allele carriers who respond initially to PPI therapy should be aware that their STAT6 haplotype is associated with higher relapse rates — this finding supports closer follow-up, consideration of higher PPI maintenance dosing, or earlier escalation to IL-4/IL-13-targeted therapy (dupilumab is FDA-approved for EoE).

The eczema herpeticum data are particularly actionable: T allele carriers with active atopic dermatitis should ensure they have a clear plan for early antiviral treatment (oral acyclovir or valacyclovir) if a disseminated vesicular eruption develops. Prompt antiviral initiation substantially reduces the severity and complications of eczema herpeticum.

Interactions

rs167769 and rs324011 operate in the same functional haplotype block; individuals carrying T alleles at both loci have the highest STAT6 expression of any genotype combination. The combined haplotype interacts additively with downstream pathway variants: IL-13 rs20541-A (hyperactive IL-13 protein) and IL-4Rα rs1801275-G (sensitized receptor) both amplify the same Th2 signaling cascade that elevated STAT6 expression executes. The IL-13 promoter variant rs1800925 is an additional upstream modulator of the same pathway.

Drug Interactions

dupilumab dose_adjustment literature
omeprazole reduced_efficacy literature

Genotype Interpretations

What each possible genotype means for this variant.

CC Normal

Standard STAT6 intron 2 alleles — typical Th2 immune tone

You carry two copies of the C allele at rs167769. The C allele does not contribute the same promoter-activating effect as the T allele in luciferase reporter assays, so your STAT6 expression remains under tighter regulatory control. This is associated with lower baseline Th2 immune activation, lower total serum IgE, and population-average risk for atopic dermatitis, asthma, and allergic rhinitis. About 40% of people of European ancestry carry this genotype. The C/C genotype also showed a protective association against hepatocellular carcinoma in NASH patients in one study, consistent with lower STAT6-mediated IL-13 signaling.

CT Intermediate

One copy of the STAT6 promoter-activating variant with modestly elevated Th2 signaling

The rs167769 T allele acts as a regulatory enhancer element in STAT6 intron 2, increasing STAT6 gene transcription. Greater STAT6 protein availability means the same IL-4 or IL-13 signal generates a larger downstream response: more IgE class switching in B cells, more eosinophil recruitment, and more sustained Th2 cytokine output. As a CT heterozygote, only one of your two STAT6 chromosomes carries this enhanced element, producing an intermediate phenotype. The clinical significance of the individual rs167769 heterozygous state is modest compared to haplotype burden across both rs167769 and rs324011 sites, but it is still measurably associated with atopic disease susceptibility in pediatric studies.

The eczema herpeticum data are relevant here: the T allele was associated with elevated risk for disseminated herpes simplex in atopic dermatitis patients (the C allele showed OR 0.65 protective). CT heterozygotes fall between the two extremes on this risk spectrum.

TT High Risk

Two copies of the STAT6 promoter-activating variant with highest intron 2 Th2 amplification

As a TT homozygote at rs167769, every STAT6 gene copy you express carries the enhancer element that increases transcriptional output. Combined with the haplotype partner rs324011-T (if also present on both chromosomes), this creates the highest achievable genetic amplification of STAT6 expression. The consequences operate at multiple levels:

First, STAT6 overexpression amplifies the IL-4/IL-13 signaling cascade — the molecular basis of allergic inflammation and IgE class switching. Serum IgE, the direct readout of this pathway, is expected to be elevated relative to CC individuals. Second, excess STAT6 signaling is mechanistically linked to impaired antiviral skin immunity. STAT6 activation suppresses interferon responses that normally control herpes simplex virus replication, explaining the observed association of STAT6 variants with eczema herpeticum susceptibility. The Howell 2011 data show that STAT6 T allele carriers have measurably higher risk for this life-threatening complication of atopic dermatitis.

In eosinophilic esophagitis, the high-LD STAT6 haplotype block (rs324011 / rs167769 / rs12368672, r²≥0.8) is associated with relapse odds 2.3–2.8 times higher than non-carriers after dose reduction of PPI maintenance therapy — a pharmacogenomic signal that has direct therapeutic implications.